肾移植受者接种第三剂SARS-CoV-2疫苗后的B细胞和T细胞反应
该研究纳入25例接种两剂BNT162b2后无体液应答的肾移植受者,第三剂给予异源ChAdOx1或同源BNT162b2。至第27天9例(36%)血清转阳,转阳者疫苗特异性B细胞和CD4+ T细胞频率显著升高,提示部分受者可从三剂接种获益。
要点
- 肾移植受者完成两剂BNT162b2无应答者,第三剂后36%(9/25)血清转阳。
- 血清转阳者 spike 特异性B细胞和CD4+ T细胞频率显著高于未转阳者。
- 第三剂后IL-2+、IL-4+及多能CD4+ T细胞频率显著增加,但记忆/效应分化未变。
核心结论
- 部分肾移植受者可从第三剂SARS-CoV-2疫苗获益,血清转阳与细胞免疫定量和定性改变相关。
- 针对免疫抑制患者的改良疫苗接种策略仍是紧迫的医学需求。
研究设计与样本
- 研究纳入25例肾移植受者,均接种两剂BNT162b2后无体液应答。
- 第三剂给予异源ChAdOx1或同源BNT162b2,随后分析血清学反应及疫苗特异性B细胞和T细胞免疫。
主要发现
- 第三剂后至第27天,25例中9例(36%)血清转阳。
- 一例患者在接种后立即出现重型COVID-19感染。
- 第三剂后7天,血清转阳者病毒刺突蛋白受体结合域特异性B细胞频率显著高于未转阳者。
- 血清转阳者刺突反应性CD4+辅助T细胞比例显著升高。
- 第三剂后IL-2+、IL-4+和多能CD4+ T细胞总体频率显著增加,记忆/效应分化未受影响。
临床怎么用
- 对两剂mRNA疫苗接种无体液应答的肾移植受者,可考虑接种第三剂以促进血清转阳和细胞免疫应答。
- 接种第三剂后仍需警惕突破性感染,研究中有接种后立即发生重型COVID-19的案例。
局限性
- 样本量小(25例),随访至第三剂后27天,为短期观察。
- 第三剂疫苗类型异源或同源不统一,可能影响免疫应答比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Accumulating evidence sugges ts solid organ transplant recipients, as opposed to the general population, show strongly impaired responsiveness toward standard SARS-CoV-2 mRNA-based vaccination, demanding alternative strategies for protectio n o f this vulnerable group. METHODS: In line with recent recommendations, a third dose of either heterologous ChAdOx1 (AstraZeneca) or homologous BNT162b2 (BioNTech) was administered to 25 kidney transplant recipients (KTR) without humoral response after two doses of BNT162b2, followed by analysis of serological responses and vaccine-specific B- and T-cell immunity. RESULTS: Nine out of 25 (36%) KTR under standard immunosuppressive treatment seroconverted until day 27 after the third vaccination, whereas one patient developed severe COVID-19 infection immediately after vaccination. Cellular analysis 7 days after the third dose showed significantly elevated frequencies of viral spike-protein receptor-binding domain-specific B cells in humor al responders as compared with nonresponders. Likewise, portions of spike-reactive CD4 + T helper cells were significantly elevated in patients who were seroconverting. Furthermore, overall frequencies of IL-2 + , IL-4 + , and polyfunctional CD4 + T cells significantly increased after the third dose, whereas memory/effector differentiation remained unaffected. CONCLUSIONS: Our data suggest a fraction of transplant recipients benefit from triple vaccination, where seroconversion is associated with quantitative and qualitative changes of cellular immunity. At the same time, the study highlights that modified vaccination approaches for immunosuppressed patients remain an urgent medical need. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/JASN/2021_11_23_briggsgriffin112321.mp3.
引用
- Schrezenmeier E, Rincon-Arevalo H, Stefanski AL, et al. B and T Cell Responses after a Third Dose of SARS-CoV-2 Vaccine in Kidney Transplant Recipients. J Am Soc Nephrol. 2021. PMID: 34667083. doi:10.1681/ASN.2021070966
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。